Cécile Voisset PhD biomedical research

Course and current status

From 2010      INSERM RESEARCHER (CR1), INSERM UMR1078, SCHOOL OF MEDICINE, UBO UNIVERSITY, BREST.

- Research projects :

  • molecular mechanisms of protein folding diseases like prion diseases.

  • Identification of molecules able to specifically induce the death of cancer cells infected with Epstein-Barr virus (EBV).

- Lab director : Pr. Marc Blondel

 

2007-2010       POST-DOCTORAL FELLOW, INSERM U613, SCHOOL OF MEDICINE, UBO UNIVERSITY, BREST.

- Research project : molecular mechanisms of protein folding diseases like prion diseases.

- Funding : young researcher grant, Inserm

- Lab director : Pr. Marc Blondel

 

2003-2007       POST-DOCTORAL FELLOW, CNRS-UMR8161, INSTITUT DE BIOLOGIE DE LILLE – INSTITUT PASTEUR DE LILLE

- Research project : Hepatitis C virus

- Funding : CNRS, ANRS

- Lab director : Jean Dubuisson

 

1999-2002      POST-DOCTORAL FELLOW, UNIVERSITY COLLEGE LONDON, WOHL VIRION CENTRE, LONDRES

- Research project : characterization of a new retrovirus isolated from patients with autoimmune diseases (Sjögren’s syndrome ; rheumatoid arthritis)

- Funding : Abbott laboratories, USA

- Lab director : Robin Weiss

 

1994-1999      PhD STUDENT, CNRS-bioMérieux LABORATORY, Lyon

- Research project : involvement of the new human endogenous retrovirus HERV-W in multiple sclerosis etiology

- Funding : Mérieux Foundation

- PhD director : Glaucià Paranhos-Baccalá

Scientific summary

Our research projects are based on the various aspects of yeast cell biology and genetics, with a particular emphasis on the study of molecular mechanisms that can be relevant to human diseases. We have set up and implemented several original yeast-based assays for various human diseases, including a yeast-based antiprion drug screening assay, and a yeast-based assay for discovering compounds that can affect the translation of the EBNA1 protein of EBV and to establish the role of mRNA translation control in MHC class I restricted antigen presentation. Our research projects involved a large network of national and international collaborations.

We first screen for active drugs using a yeast-based assay, and then evaluate the activity of hits on ex vivo assays (cell culture) as well as in vivo in relevant animal models. Drugs active in the yeast- and mammalian-based assays are further used as tool to identify their cellular target(s).

For our different research projects, we use yeast-based drug and genetic screening assays, drug testing, affinity chromatography on immobilized drugs, yeast genetics and cell biology.

Image d’exemple